GTI-850
Autoimmune Conjunctivitis / Dry Eye Disease
Key Facts
About GSNO Therapeutics
GSNO Therapeutics is a preclinical-stage biotech developing GSNOR inhibitors, with GTI-850 as its lead asset. The platform is based on increasing endogenous GSNO levels, a natural signaling molecule, to achieve therapeutic effects across 56 identified activities in 26 animal models, including ophthalmology, inflammatory bowel disease, and age-related conditions. The company is preparing for initial clinical trials in autoimmune conjunctivitis and dry eye, positioning itself as a potential developer of safer alternatives to steroids and JAK inhibitors.
View full company profileAbout GSNO Therapeutics
GSNO Therapeutics is a preclinical-stage biotech developing GSNOR inhibitors, with GTI-850 as its lead asset. The platform is based on increasing endogenous GSNO levels, a natural signaling molecule, to achieve therapeutic effects across 56 identified activities in 26 animal models, including ophthalmology, inflammatory bowel disease, and age-related conditions. The company is preparing for initial clinical trials in autoimmune conjunctivitis and dry eye, positioning itself as a potential developer of safer alternatives to steroids and JAK inhibitors.
View full company profileAbout GSNO Therapeutics
GSNO Therapeutics is a preclinical-stage biotech developing GSNOR inhibitors, with GTI-850 as its lead asset. The platform is based on increasing endogenous GSNO levels, a natural signaling molecule, to achieve therapeutic effects across 56 identified activities in 26 animal models, including ophthalmology, inflammatory bowel disease, and age-related conditions. The company is preparing for initial clinical trials in autoimmune conjunctivitis and dry eye, positioning itself as a potential developer of safer alternatives to steroids and JAK inhibitors.
View full company profileAbout GSNO Therapeutics
GSNO Therapeutics is a preclinical-stage biotech developing GSNOR inhibitors, with GTI-850 as its lead asset. The platform is based on increasing endogenous GSNO levels, a natural signaling molecule, to achieve therapeutic effects across 56 identified activities in 26 animal models, including ophthalmology, inflammatory bowel disease, and age-related conditions. The company is preparing for initial clinical trials in autoimmune conjunctivitis and dry eye, positioning itself as a potential developer of safer alternatives to steroids and JAK inhibitors.
View full company profile